ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1007

Change in Semi-Quantitative Imaging Biomarkers Predicts Knee Osteoarthritis Progression: Data from the Fnih OA Biomarkers Consortium

Jamie E. Collins1, Elena Losina2, Michael C. Nevitt3, Frank W. Roemer4, Ali Guermazi4, John A. Lynch5, Jeffrey N. Katz2, C. Kent Kwoh6, Joanne M. Jordan7, Virginia Kraus8 and David Hunter9, 1Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3University of California, San Francisco, San Francisco, CA, 4Boston University School of Medicine, Boston, MA, 5University of California San Francisco, San Francisco, CA, 6University of Arizona, Tucson, AZ, 7Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 8Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 9University of Sydney, Sydney, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers and osteoarthritis, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoarthritis - Clinical Aspects I: Imaging and Epidemiology

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:
Semi-quantitative
scoring of magnetic resonance images (MRIs) is a valuable method for performing
multi-feature assessment of the knee joint. The goal of this study was to
investigate the ability of change in semi-quantitative knee MRI biomarkers over
24 months to predict knee osteoarthritis (OA) progression over 48 months.  

Methods:
This
analysis was done as a part of the fNIH-funded OA Biomarkers Consortium
case-control study. We selected a predetermined number of index knees, one knee
per subject, in four different knee outcome groups: 1) knees with both radiographic
and pain progression; 2) knees with radiographic but not pain progression; 3)
knees with pain but not radiographic progression; 4) knees with neither
radiographic nor pain progression. For the purposes
of this analysis we used the single comparison, comparing knees with both
radiographic and pain progression (cases) vs. everybody else (controls). MRIs
were read according to the MRI Osteoarthritis Knee Score (MOAKS) scoring system
in sequential order unblinded to time point of acquisition but blinded to group
assignment. This analysis focused on change in several joint features: 1) bone
marrow lesions (BMLs), 2) cartilage thickness, 3) cartilage surface area, 4)
effusion-synovitis, 5) meniscus morphology, 6) meniscus extrusion, 7)
osteophytes size, and 8) Hoffa-synovitis. We used logistic regression to
examine the association between each biomarker and case status. Multivariable
models were built in a hierarchical fashion, with the best performing
biomarkers from univariate analyses added to the model first (performance based
on p-value, OR and c-statistics).
  Results:
We used
the data from 194 cases and 406 controls, mean age 62 years, 59% females, 51%
K-L 2 and 37% K-L 3. All joint features considered were significantly
associated with case status in univariate analyses, and all features were
progressed to multivariable modeling. We built several hierarchical models with
c-statistics ranging from 0.686 to 0.725 (Table). Results of multivariable
modeling revealed that changes from baseline to 24 months in cartilage
thickness, cartilage surface area, meniscal morphology, effusion-synovitis, and Hoffa-synovitis
independently predicted knee OA progression (case status). BMLs, osteophytes,
and meniscal extrusion did not exhibit a statistically significant association
with being a case in multivariable models when cartilage thickness and surface
area and meniscal morphology were included in the model.

Conclusion: Both loss of
cartilage thickness and cartilage surface area worsening over 24 months were
independently associated with knee OA progression over 48 months. In addition,
changes over 24 months in semi-quantitative measures on MRI related to meniscus
morphology, effusion-synovitis, and Hoffa-synovitis were associated with
progression of knee OA in multivariable models.


Disclosure: J. E. Collins, None; E. Losina, None; M. C. Nevitt, None; F. W. Roemer, Boston Imaging Core Lab, LLC, 1; A. Guermazi, Boston Imaging Core Lab, LLC, 1,TissueGene, 5,OrthoTrophix, 5,MerckSerono, 5,Genzyme Corporation, 5; J. A. Lynch, None; J. N. Katz, None; C. K. Kwoh, Novartis Pharmaceutical Corporation, 5,Astra-Zeneca, 2; J. M. Jordan, None; V. Kraus, None; D. Hunter, DJO, 7.

To cite this abstract in AMA style:

Collins JE, Losina E, Nevitt MC, Roemer FW, Guermazi A, Lynch JA, Katz JN, Kwoh CK, Jordan JM, Kraus V, Hunter D. Change in Semi-Quantitative Imaging Biomarkers Predicts Knee Osteoarthritis Progression: Data from the Fnih OA Biomarkers Consortium [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/change-in-semi-quantitative-imaging-biomarkers-predicts-knee-osteoarthritis-progression-data-from-the-fnih-oa-biomarkers-consortium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/change-in-semi-quantitative-imaging-biomarkers-predicts-knee-osteoarthritis-progression-data-from-the-fnih-oa-biomarkers-consortium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology